Next-Generation Antibody Therapeutics Market Size
|2019 - 2029
|Base Year For Estimation
|Fastest Growing Market
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Next-Generation Antibody Therapeutics Market Analysis
Over the next few years, the market for next-generation antibody therapeutics is expected to register a CAGR of 12.1%.
The COVID-19 outbreak put an immense burden on the healthcare infrastructure to develop advanced treatments and vaccines. Owing to the high specificity and reliability of next-generation antibody therapeutics, monoclonal antibodies (mAbs) emerged as powerful tools to treat and detect numerous diseases, including SARS and CoV-2, which resulted in the evolution of the next-generation antibody therapeutics sector. As per the article published in January 2022 in the Journal of Biomedical Science, many researchers have started to urgently develop antibody-based assays for the detection of SARS-CoV-2 and Ab therapeutics for use as COVID-19 treatment agents. For instance, in September 2022, AstraZeneca's Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination, has been recommended for marketing authorization in the European Union for the treatment of adults and adolescents, aged 12 years and older, weighing at least 40 kg, with COVID19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID19. Hence, the COVID-19 pandemic was anticipated to positively impact the next-generation antibody therapeutics market in the coming years.
The major factor attributing to the growth of the market is the increase in the prevalence of different chronic diseases such as rheumatoid arthritis, inflammatory bowel disorder, Crohn's disease, and cancer. According to the research published by Medscape in January 2022, the annual incidence rate of rheumatoid arthritis is approximately 3 cases per 10,000 people, and the prevalence rate is approximately 1% globally. Furthermore, the American Cancer Society published the statistics in January 2021, estimating more than 1.9 million new cancer cases to be diagnosed and 609,360 cancer deaths in the United States in 2022. Due to their enhanced efficacy, increased safety, and ability to deliver targeted treatment, next-generation antibody therapies are primarily used to treat chronic diseases, including cancer and autoimmune disorders. Thus, it is anticipated that the studied market would expand in a lucrative way due to the rising prevalence of chronic diseases and rare disorders, where next-generation antibodies serve as the predominant therapy.
Leading biotechnology and pharmaceutical corporations are increasingly funding the creation of new therapeutic antibodies to fight inflammatory illnesses, cancer, and autoimmune disorders. For instance, in November 2022, Seagen announced the US Food and Drug Administration's (FDA) approval of a new indication for brentuximab vedotin, ADCETRIS, for children with previously untreated high-risk Hodgkin lymphoma. In November 2022, ImmunoGen announced that the U.S. FDA had granted accelerated approval for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of platinum-resistant ovarian cancer in adults. Additionally, in July 2022, F-star Therapeutics announced a license agreement to grant Takeda a worldwide, exclusive, royalty-bearing license to research, develop, and commercialize a bispecific next-generation antibody against an immuno-oncology target using F-star's proprietary Fcab and mAb2 platforms. In March 2022, Bayer announced its plans to spend EUR 2 billion over the next three years to expand its next-gen manufacturing capabilities.
Therefore, the studied market is likely to witness growth over the forecast period due to several factors, such as growing advancements in monoclonal antibody technology, rising incidences of chronic disorders, and increasing initiatives for the discovery and development of next-generation antibody therapeutics. However, strict regulations on the approval of these therapeutics, coupled with the inflated costs of the next generation of antibody therapeutics, are expected to hinder market growth during the study period.
Next-Generation Antibody Therapeutics Market Trends
This section covers the major market trends shaping the Next-Generation Antibody Therapeutics Market according to our research experts:
Antibody-Drug Conjugates Segment is Expected to Hold the Largest Market Share in the Next-Generation Antibody Therapeutics Market
Antibody-Drug Conjugates (ADC) are a significant advancement in next-generation antibody therapeutics because ADC technology combines the cytotoxic potential of chemotherapy with the advantageous properties of antibodies, resulting in ADCs with high specificity and efficiency.Next-generation antibody therapies for the treatment of cancer are mostly manufactured using ADC technology. ADCs are manufactured by linking an anti-cancer drug or another therapeutic substance to an antibody or antibody fragment. For instance, according to research published in June 2021 in The Oncologist, sacituzumab govitecan, an antibody-drug conjugate composed of a humanized anti-Trop-2 antibody conjugated to SN38, proved to be an effective and generally well-tolerated agent that represents a promising novel therapy for patients with metastatic triple-negative breast cancer.
The high demand for antibody-based cancer therapy, along with the increasing incidence of breast cancer globally, new technological advancements, and a rapid rise in the number of these conjugates under clinical trials, will likely drive the antibody-drug conjugates (ADC) segment to dominate the market during the forecast period. According to the statistics reported by BreastCancer.org in October 2022, breast cancer is currently the most common cancer globally, accounting for 12.5% of all new annual cancer cases worldwide. Similarly, the American Cancer Society published the study in October 2022, reporting an estimated 287,850 new cases of invasive breast cancer expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive (in situ) breast cancer annually. Due to these strong demands, the market will grow quickly over the next few years.
The rising demand for these antibody therapeutics has resulted in the rapid increase of new drug approvals for ADCs. Several players are actively involved in the development of next-generation antibody therapeutics using ADC technology through various strategies. For instance, in February 2022, Mersana Therapeutics Inc. announced its partnership with Janssen Pharmaceutical Companies for the research and development of novel ADCs to treat numerous cancers. Additionally, in June 2022, ImmunoGen Inc. announced a multi-year research collaboration with Oxford BioTherapeutics to develop novel antibody-drug conjugates. These kinds of collaborations are fueling the growth of the segment and propelling the next-generation antibody therapeutics market's revenue in the forecast period.
North America is Expected to Dominate the Next-Generation Antibody Therapeutics Market
North America is anticipated to dominate the overall next-generation antibody therapeutics market throughout the forecast period. The dominance is due to several factors, such as a rise in auto-immune diseases, increased healthcare expenditure, new product launches, and continuous growth in R&D activities with the rise in the application of these therapeutics in the treatment of various disorders.
Further, the growing incidence of chronic disorders such as cancer and asthma is driving the next-generation antibody therapeutics market. According to a report published in September 2022 by the Asthma and Allergy Foundation of America, approximately 25 million people in the United States have asthma each year, accounting for one in every thirteen Americans.Further, as per the report published by Breast Cancer.Org in October 2022, there are more than 3.8 million women in the U.S. with a history of breast cancer as of January 2022. Thus, the escalation in the prevalence of chronic diseases in the region is driving the size of the sector.
Moreover, the presence of significant companies in the region, the rapid approval of next-generation antibody therapies, and the availability of reputable research centers all contribute to the market's expansion. According to the article published in November 2022 in Silicon Republic, as of 2021, the U.S. FDA has approved its 100th monoclonal antibody therapeutic. For instance, in August 2022, AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) will be approved in the United States for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. In December 2022, Pyxis Oncology, Inc. received clearance from the U.S. FDA to initiate Phase 1 clinical trials for its Investigational New Drug (IND) application of PYX-201, a novel antibody-drug conjugate (ADC) product candidate. The market is anticipated to advance in the next few years, driven by several approvals and many products currently in the pipeline. Furthermore, the presence of advanced healthcare infrastructure and well-established direct reimbursement policies is also expected to contribute significantly to market revenue throughout the forecast period.
Next-Generation Antibody Therapeutics Industry Overview
The market for next-generation antibody therapeutics is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are acquiring other companies to consolidate their market positions across the globe, while others are launching new products. Some of the companies that are currently dominating the market are Amgen Inc., AstraZeneca Plc., Bayer AG, Biogen, Bristol-Myers Squibb Company, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., ImmunoGen Inc., Kyowa Hakko Kirin Co., Ltd., Pfizer Inc., Seagen Inc., and Xencor, Inc., among others.
Next-Generation Antibody Therapeutics Market Leaders
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
*Disclaimer: Major Players sorted in no particular order
Next-Generation Antibody Therapeutics Market News
- December 2022: Sorrento Therapeutics, Inc. received clearance from the U.S. FDA to initiate clinical trials with its next-generation mRNA (STI-1557) vaccine against SARS-CoV-2 Omicron variants.
- July 2022: Byondis received biologics license application acceptance from the U.S. FDA for Vic-Trastuzumab Duocarmazine (SYD985), an antibody-drug conjugate, as a treatment for patients with HER2-positive advanced breast cancer.
Next-Generation Antibody Therapeutics Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Cancer
4.2.2 Rising Prevalence of Autoimmune Diseases
4.2.3 Technological Progressions in Antibody Therapeutics
4.3 Market Restraints
4.3.1 Stringent Regulatory Framework
4.3.2 High costs of Next-Generation Antibody Therapeutics
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Therapeutic Area
5.2 By Technology
5.2.1 Antibody-Drug Conjugates (ADCs)
5.2.2 Bispecific Antibodies (BsAbs)
5.2.3 Fc-Engineered Antibodies
5.2.4 Antibody Fragments and Antibody-Like Proteins (AF & ALPs)
5.2.5 Biosimilar Antibody Products
5.3.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.3.4 Middle East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle East and Africa
5.3.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 AstraZeneca Plc.
6.1.3 Bayer AG
6.1.5 Bristol-Myers Squibb Company
6.1.6 GlaxoSmithKline Plc.
6.1.7 F. Hoffmann-La Roche Ltd
6.1.8 ImmunoGen Inc.
6.1.9 Kyowa Hakko Kirin Co., Ltd.
6.1.10 Pfizer Inc.
6.1.11 Seagen Inc.
6.1.12 Xencor, Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Next-Generation Antibody Therapeutics Market Research FAQs
What is the current Next-Generation Antibody Therapeutics Market size?
The Next-Generation Antibody Therapeutics Market is projected to register a CAGR of 12.10% during the forecast period (2024-2029)
Who are the key players in Next-Generation Antibody Therapeutics Market?
AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Pfizer, Inc. and Seagen Inc. are the major companies operating in the Next-Generation Antibody Therapeutics Market.
Which is the fastest growing region in Next-Generation Antibody Therapeutics Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Next-Generation Antibody Therapeutics Market?
In 2024, the North America accounts for the largest market share in Next-Generation Antibody Therapeutics Market.
What years does this Next-Generation Antibody Therapeutics Market cover?
The report covers the Next-Generation Antibody Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Next-Generation Antibody Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Next-Generation Antibody Therapeutics Industry Report
Statistics for the 2024 Next-Generation Antibody Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Next-Generation Antibody Therapeutics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.